



Press release

# FURTHER STRENGTHENING OF THE FINANCIAL STRUCTURE

## Non-dilutive financing totalling €14 million dedicated to the acceleration of development

Dijon, 9 January 2023 at 8am (CET)

**CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company that is developing and will soon be marketing a portfolio of drug / device combinations for use in emergency situations,** is continuing to strengthen its financial resources in line with its business plan to support the very marked acceleration of its development.

Following the great success of the €4.09 million capital increase, Crossject is proud to announce the completion of a combined non-dilutive financial transaction of €14 million.

The transaction includes various loans granted by its long-standing banks (Caisse d'Épargne and BNP), Société Générale and BPI, with amortisation periods ranging from 5 to 10 years, and with nearly 85% of the total available immediately.

Patrick Alexandre, Chairman of the Management Board, said: *“On top of the confidence of our lenders, whom I would particularly like to thank for their support for this transaction, our Group has acquired new resources to successfully complete its roadmap, and above all to support an unparalleled ramp-up with the implementation of the agreement with BARDA (contract no. 75A50122C00031).”*

### Contacts:

**Crossject**  
Patrick Alexandre  
[info@crossject.com](mailto:info@crossject.com)

**Investor relations**  
**AELIUM**  
Jérôme Gacoin +33 (0) 1 75 77 54 67  
[crossject@aelium.fr](mailto:crossject@aelium.fr)

**Press relations**  
**Buzz & Compagnie**  
Mélanie Voisard +33 (0)6 12 52 53 15  
[melanie.voisard@buzzetcompagnie.com](mailto:melanie.voisard@buzzetcompagnie.com)  
Christelle Distinguin +33 (0)6 09 96 51 70  
[christelle.distinguin@buzzetcompagnie.com](mailto:christelle.distinguin@buzzetcompagnie.com)



## About CROSSJECT • [www.crossject.com](http://www.crossject.com)

CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, overdose, allergic shock, severe migraine and asthma attack. Thanks to its patented needlefree self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014; it receives funding from the United States BARDA (Biomedical Advanced Research and Development Authority) and from Bpifrance.